** Shares of gene therapy developer Rocket Pharmaceuticals RCKT.O rise 1.8% to $3.42 premarket
** Company says it is reducing headcount by about 30% and its 12-month cash burn by nearly 25%
** Adds it is restructuring its drug development program to focus on its cardiovascular therapies and its main gene therapy candidate, kresladi, being developed for the treatment of a rare immunodeficiency disorder called severe leukocyte adhesion deficiency
** Up to last close, stock down 73.3% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.